HHS Secretary Kennedy Moves to Overturn FDA Peptide Restrictions Amid Expert Pushback

Health and Human Services Secretary Robert F. Kennedy Jr. is preparing to reverse a 2023 Food and Drug Administration ruling that prohibited compounding pharmacies from dispensing 19 specific peptide drugs. Kennedy has publicly labeled the agency's previous decision as illegal, arguing that the FDA lacked the necessary safety signals to justify the ban and exceeded its authority by considering the efficacy of the substances. As a vocal proponent of these amino acid chains, which are frequently marketed to fitness and wellness enthusiasts for anti-aging and performance benefits, Kennedy maintains that the government overstepped its regulatory bounds.

However, former FDA officials are challenging Kennedy’s characterization of the agency’s historical process. Experts, including former acting commissioner Janet Woodcock, emphasize that the 2023 decision was based on documented safety concerns and that federal regulations explicitly require the agency to evaluate both safety and effectiveness before permitting the use of such compounds. Critics warn that reversing these restrictions without new scientific evidence could mislead the public regarding the safety of untested drugs. While social media influencers continue to drive high demand for these products, the potential policy shift remains a point of contention between the current administration and veteran regulators who fear a breakdown in established drug safety standards.